Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney

von Heerspink, Hiddo J L
Veröffentlicht in Nephrol Dial Transplant (2019)

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform

von Heerspink, Hiddo J.L., Perkovic, Vlado
Veröffentlicht in Clin J Am Soc Nephrol (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease

von Heerspink, Hiddo J. L., De Zeeuw, Dick
Veröffentlicht in Diabetologia (2016)

Treating diabetic complications; from large randomized clinical trials to precision medicine

von Heerspink, Hiddo J. L., de Zeeuw, Dick
Veröffentlicht in Diabetes Obes Metab (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy

von de Zeeuw, Dick, Heerspink, Hiddo J L
Veröffentlicht in Nephrol Dial Transplant (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

von Heerspink, Hiddo J. L., List, James, Perkovic, Vlado
Veröffentlicht in Diabetes Obes Metab (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease

von Heerspink, Hiddo J L, Fouque, Denis, Wanner, Christoph
Veröffentlicht in Nephrol Dial Transplant (2020)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease

von Pena, Michelle J., Mischak, Harald, Heerspink, Hiddo J. L.
Veröffentlicht in Diabetologia (2016)

ACCORDION: Ensuring That We Hear the Music Clearly

von Wong, Muh Geot, Heerspink, Hiddo J.L., Perkovic, Vlado
Veröffentlicht in Clin J Am Soc Nephrol (2018)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

von Koomen, Jeroen V., Stevens, Jasper, Heerspink, Hiddo J.L.
Veröffentlicht in Br J Clin Pharmacol (2020)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges

von Tye, Sok Cin, Denig, Petra, Heerspink, Hiddo J L
Veröffentlicht in Nephrol Dial Transplant (2021)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

von Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Veröffentlicht in Curr Diab Rep (2018)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

von Perco, Paul, Pena, Michelle, Heerspink, Hiddo J.L., Mayer, Gert
Veröffentlicht in Kidney Int Rep (2018)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus

von Vinke, Joanna Sophia J., Heerspink, Hiddo J.L., de Borst, Martin H.
Veröffentlicht in Curr Opin Nephrol Hypertens (2019)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives

von Martono, Doti P., Heerspink, Hiddo J.L., Hak, Eelko, Denig, Petra, Wilffert, Bob
Veröffentlicht in Diabetes Obes Metab (2019)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies

von Olde Engberink, Rik H. G., Heerspink, Hiddo J. L., de Zeeuw, Dick, Vogt, Liffert
Veröffentlicht in Br J Clin Pharmacol (2016)

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

von Heerspink, Hiddo J. L., Desai, Mehul, Jardine, Meg, Balis, Dainius, Meininger, Gary, Perkovic, Vlado
Veröffentlicht in J Am Soc Nephrol (2017)

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

von Weldegiorgis, Misghina, de Zeeuw, Dick, Dwyer, Jamie P., Mol, Peter, Heerspink, Hiddo J.L.
Veröffentlicht in Clin J Am Soc Nephrol (2017)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

von Mol, Peter G. M., Thompson, Aliza, Heerspink, Hiddo J. L., Leufkens, Hubert G. M.
Veröffentlicht in Diabetes Obes Metab (2018)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

von Kroonen, Marjolein Y. A. M., Stevens, Jasper, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Veröffentlicht in Diabetes Obes Metab (2019)